AUS
NZ
UK
CA
USA
IND
Highlights
Sareum Holdings Plc confirmed the exercise of warrants, leading to the issue of new ordinary shares.
The company has applied for admission of the new shares to trading on the London Stock Exchange.
Updated share capital figures reflect the enlarged issued share base of Sareum Holdings Plc.
Sareum Holdings Plc operates within the biotechnology and pharmaceutical research sector, with its listing connected to the FTSE All Share index. The company is engaged in developing drug candidates for the treatment of cancer and autoimmune diseases. The latest corporate announcement highlights an update regarding warrants and their related share issuance.
Sareum Holdings Plc (LSE:SAR) reported the exercise of warrants, which resulted in the allotment of additional ordinary shares. Each new share has been created in line with the company’s previously announced terms regarding the warrants. The issued shares will rank equally with the existing ordinary shares already admitted to trading.
Admission of Shares
The company confirmed that it has applied for the newly issued ordinary shares to be admitted to trading on the London Stock Exchange. The admission is expected to take effect shortly after the application process is completed. Once admitted, the shares will be fully tradable in the same manner as the company’s existing ordinary shares.
This admission is a procedural step to ensure that the company’s enlarged share capital is reflected on the exchange. It also provides clarity regarding the company’s updated issued share structure following the warrant exercise.
Enlarged Issued Share Capital
The exercise of warrants has contributed to an increase in the company’s issued share capital. The updated share base now incorporates the newly allotted shares, ensuring all stakeholders are informed of the current structure. This enlarged capital forms the basis for the company’s ongoing corporate governance disclosures and regulatory filings.
Shareholders and market participants are able to reference the updated total when calculating any notifiable interests or thresholds, in accordance with the Disclosure Guidance and Transparency Rules. These updates form part of the company’s compliance with standard market regulations, ensuring transparency regarding its shareholding base.
Corporate Communication
The announcement also confirms that the new shares rank pari passu with the existing ordinary shares. This means that each share, whether newly issued or already existing, holds identical rights in terms of voting, participation, and entitlement. Such updates are standard communication by companies on the London Stock Exchange to maintain market transparency.
These updates reflect Sareum Holdings Plc’s adherence to disclosure obligations and regulatory standards. Corporate announcements of this nature provide clarity to the market about changes to issued share capital, ensuring stakeholders are kept up to date with structural adjustments to the company’s equity base.
Frequently Asked Questions
- What does Sareum Holdings Plc do?
Sareum Holdings Plc focuses on developing new therapies for cancer and autoimmune diseases. - What was announced regarding Sareum Holdings Plc shares?
The company announced the exercise of warrants and the issue of new ordinary shares. - Which index includes Sareum Holdings Plc?
Sareum Holdings Plc is part of the FTSE All Share index.
